These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31909673)

  • 21. Preliminary evidence of hippocampal damage in chronic users of ecstasy.
    den Hollander B; Schouw M; Groot P; Huisman H; Caan M; Barkhof F; Reneman L
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):83-5. PubMed ID: 21444322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users.
    Schilt T; de Win MM; Jager G; Koeter MW; Ramsey NF; Schmand B; van den Brink W
    Psychol Med; 2008 Sep; 38(9):1309-17. PubMed ID: 17988417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands.
    Brunt TM; Niesink RJ; van den Brink W
    Int J Drug Policy; 2012 Mar; 23(2):134-40. PubMed ID: 21741814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 26. Evidence for significant polydrug use among ecstasy-using college students.
    Wish ED; Fitzelle DB; O'Grady KE; Hsu MH; Arria AM
    J Am Coll Health; 2006; 55(2):99-104. PubMed ID: 17017306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.
    Parrott AC; Buchanan T; Scholey AB; Heffernan T; Ling J; Rodgers J
    Hum Psychopharmacol; 2002 Aug; 17(6):309-12. PubMed ID: 12404677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].
    Nielsen JC; Nicholson K; Pitzner-Jørgensen BL; Undén M
    Ugeskr Laeger; 1995 Feb; 157(6):724-7. PubMed ID: 7701630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
    Fox HC; Parrott AC
    J Psychopharmacol; 2003 Jun; 17(2):242-4. PubMed ID: 12870575
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses.
    Murphy PN; Bruno R; Ryland I; Wareing M; Fisk JE; Montgomery C; Hilton J
    Hum Psychopharmacol; 2012 Mar; 27(2):113-38. PubMed ID: 22389076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deterioration of executive functioning in chronic ecstasy users; evidence for multiple drugs effects.
    Verbaten MN
    Curr Drug Abuse Rev; 2010 Sep; 3(3):129-38. PubMed ID: 21054259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
    Buchert R; Obrocki J; Thomasius R; Väterlein O; Petersen K; Jenicke L; Bohuslavizki KH; Clausen M
    Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDMA, cortisol, and heightened stress in recreational ecstasy users.
    Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
    Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the use of ecstasy and hallucinogens increasing? Results from a community study.
    Schuster P; Lieb R; Lamertz C; Wittchen HU
    Eur Addict Res; 1998 Mar; 4(1-2):75-82. PubMed ID: 9740820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is a dose of ecstasy?
    Cole JC; Sumnall HR; Wagstaff GF
    J Psychopharmacol; 2002 Jun; 16(2):189-90. PubMed ID: 12095080
    [No Abstract]   [Full Text] [Related]  

  • 36. The epidemiology of ecstasy use and harms in Australia.
    Degenhardt L; Roxburgh A; Dunn M; Campbell G; Bruno R; Kinner SA; George J; Quinn B; White N; Topp L
    Neuropsychobiology; 2009; 60(3-4):176-87. PubMed ID: 19893334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naïve controls.
    Morgan MJ; Impallomeni LC; Pirona A; Rogers RD
    Neuropsychopharmacology; 2006 Jul; 31(7):1562-73. PubMed ID: 16292322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
    Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
    Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002.
    Schifano F; Oyefeso A; Corkery J; Cobain K; Jambert-Gray R; Martinotti G; Ghodse AH
    Hum Psychopharmacol; 2003 Oct; 18(7):519-24. PubMed ID: 14533133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.